News | August 06, 2025
Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr
Cenexi reports an EBITDA breakeven for the quarter
Cenexi reports an EBITDA breakeven for the quarter
The submission is supported by positive results from the Phase 3 AMPLIFY trial
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
This will be Aster’s fifth hospital in Bengaluru
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
The expansion will bring together talent in AI, data science, and engineering to build the digital foundation needed to accelerate drug discovery and delivery
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
Baruah will lead strategy, growth, and transformation across the HLS vertical, focusing on expanding digital health capabilities and accelerating AI adoption
7-OH is a concentrated byproduct of the kratom plant and has shown potential for abuse by binding to opioid receptors
Subscribe To Our Newsletter & Stay Updated
